HomeCompareGBCHF vs ABBV

GBCHF vs ABBV: Dividend Comparison 2026

GBCHF yields 4000000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBCHF wins by $4.994481689239762e+42M in total portfolio value
10 years
GBCHF
GBCHF
● Live price
4000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.994481689239762e+42M
Annual income
$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00
Full GBCHF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GBCHF vs ABBV

📍 GBCHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBCHFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBCHF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBCHF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBCHF
Annual income on $10K today (after 15% tax)
$340,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,245,100,666,965,326,000,000,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GBCHF beats the other by $4,245,100,666,965,326,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBCHF + ABBV for your $10,000?

GBCHF: 50%ABBV: 50%
100% ABBV50/50100% GBCHF
Portfolio after 10yr
$2.497240844619881e+42M
Annual income
$2,497,118,039,391,368,600,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GBCHF
No analyst data
Altman Z
-1713.2
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBCHF buys
0
ABBV buys
0
No recent congressional trades found for GBCHF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBCHFABBV
Forward yield4000000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.994481689239762e+42M$102.3K
Annual income after 10y$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$4.994465620575748e+42M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GBCHF vs ABBV ($10,000, DRIP)

YearGBCHF PortfolioGBCHF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$400,010,700$400,000,000.00$11,550$430.00+$400.00MGBCHF
2$14,954,099,039,486$14,953,671,028,037.38$13,472$627.96+$14954099.03MGBCHF
3$522,475,570,786,797,700$522,459,569,900,825,500.00$15,906$926.08+$522475570786.78MGBCHF
4$17,060,387,015,284,700,000,000$17,059,827,966,423,956,000,000.00$19,071$1,382.55+$17060387015284700.00MGBCHF
5$520,629,757,399,644,800,000,000,000$520,611,502,785,538,400,000,000,000.00$23,302$2,095.81+$520629757399644831744.00MGBCHF
6$14,848,629,939,995,690,000,000,000,000,000$14,848,072,866,155,271,000,000,000,000,000.00$29,150$3,237.93+$1.4848629939995692e+25MGBCHF
7$395,786,651,827,842,740,000,000,000,000,000,000$395,770,763,793,806,900,000,000,000,000,000,000.00$37,536$5,121.41+$3.9578665182784276e+29MGBCHF
8$9,859,464,902,403,675,000,000,000,000,000,000,000,000$9,859,041,410,686,219,000,000,000,000,000,000,000,000.00$50,079$8,338.38+$9.859464902403675e+33MGBCHF
9$229,542,483,200,980,940,000,000,000,000,000,000,000,000,000$229,531,933,573,535,350,000,000,000,000,000,000,000,000,000.00$69,753$14,065.80+$2.2954248320098093e+38MGBCHF
10$4,994,481,689,239,762,000,000,000,000,000,000,000,000,000,000,000$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$4.994481689239762e+42MGBCHF

GBCHF vs ABBV: Complete Analysis 2026

GBCHFStock

Metaverse Capital Corp. engages in controlling computing power for mining cryptocurrencies, operating masternodes/servicenodes, and providing witness services. The company's professional consultancy services include crowdsale administration services, as well as advisory services related to the development of blockchain networks. It also provides digital asset pooling operations that combines digital assets from various clients to operate masternodes on two-tier proof-of-stake blockchain networks. The company was formerly known as Global Blockchain Mining Corp. and changed its name to Metaverse Capital Corp. in May 2019. Metaverse Capital Corp. was incorporated in 2017 and is based in Vancouver, Canada.

Full GBCHF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GBCHF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBCHF vs SCHDGBCHF vs JEPIGBCHF vs OGBCHF vs KOGBCHF vs MAINGBCHF vs JNJGBCHF vs MRKGBCHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.